Acute and chronic postoperative pain and functional disability persisted among patients who underwent posterior spinal fusion despite multimodal analgesic management.
Theradaptive, a Maryland-based, privately held, clinical-stage biologics company, today announced the initiation of patient dosing in Maryland for the ongoing OASIS Phase I/II clinical trial assessing ...